文献速递肝病

失代偿期肝硬化细菌感染的多因素机制

The multifactorial mechanisms of bacterial infection in decompensated cirrhosis.
PubMed 文献 · J Hepatol · 2021-01-01

综述阐述失代偿期肝硬化患者因免疫功能紊乱易发生细菌感染,感染常源于先天免疫屏障破损和免疫细胞清除不足,导致细菌及产物移位至体循环,而肝内炎症预激活状态使患者易进展为器官衰竭。早期识别和及时使用合适抗生素可降低特定感染死亡率,但多重耐药感染出现使抗生素合理使用仍很必要。近年发现免疫细胞分子靶点或可增强功能、理论上预防感染,相关临床试验正在进行。

要点

  • 失代偿期肝硬化患者因免疫功能紊乱,细菌感染风险高且预示终末期开始。
  • 感染源于先天免疫屏障破损和免疫细胞清除不足,导致细菌及产物移位至体循环。
  • 早期识别感染并及时使用合适抗生素可降低特定感染死亡率,但需警惕多重耐药。

核心结论

  • 失代偿期肝硬化患者因免疫功能紊乱易发生细菌感染,感染预示疾病终末期开始。
  • 早期识别和及时使用合适抗生素可降低特定感染死亡率,但多重耐药感染出现使合理使用抗生素仍很必要。
  • 免疫细胞分子靶点或可增强功能、理论上预防感染,相关临床试验正在进行。

研究设计与样本

  • 综述,回顾失代偿期肝硬化患者细菌感染的易感机制、临床意义及预防或治疗潜在靶点。

主要发现

  • 感染通常源于先天免疫屏障破损和免疫细胞清除不足,导致细菌及细菌产物移位至体循环。
  • 肝硬化患者肝内持续炎症使免疫系统预激活,感染时特别易发生器官衰竭。
  • 早期识别细菌感染和及时使用合适抗生素降低了失代偿期肝硬化患者特定感染的死亡率。
  • 肝硬化人群中多重耐药感染出现,使合理使用抗生素治疗仍很必要。
  • 近年研究发现免疫细胞分子靶点或可增强功能、理论上预防感染,临床试验正在区分靶向分子有益效应与脱靶效应。

临床怎么用

  • 对失代偿期肝硬化患者应早期识别细菌感染并及时使用合适抗生素以降低特定感染死亡率。
  • 鉴于多重耐药感染出现,抗生素治疗仍需合理使用。
  • 免疫细胞分子靶点或可增强功能、理论上预防感染,但尚待临床试验明确有益效应与脱靶效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Infections, due to a dysfunctional immune response, pose a great risk to patients with decompensated cirrhosis and herald the beginning of the terminal phase of this disease. Infections typically result from breaches in innate immune barriers and inadequate clearance by immune cells. This leads to bacterial and bacterial product translocation to the systemic circulation, which is already primed by ongoing hepatic inflammation in patients with cirrhosis, who are particularly prone to developing organ failure in the presence of an infection. Early identification of bacterial infection, along with the prompt use of appropriate antibiotics, have reduced the mortality associated with certain infections in patients with decompensated cirrhosis. Judicious use of antibiotic therapy remains imperative given the emergence of multidrug-resistant infections in the cirrhotic population. Important research over the last few years has identified molecular targets on immune cells that may enhance their function, and theoretically prevent infections. Clinical trials are ongoing to delineate the beneficial effects of targeted molecules from their off-target effects. Herein, we review the mechanisms that predispose patients with cirrhosis to bacterial infections, the clinical implications of infections and potential targets for the prevention or treatment of infections in this vulnerable population.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Van der Merwe S, Chokshi S, Bernsmeier C, et al. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. J Hepatol. 2021. PMID: 34039494. doi:10.1016/j.jhep.2020.11.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。